Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study
August 14, 2018 07:48 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
May 31, 2017 07:30 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 31, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) announced today the issuance of European Patent No. 1615623 titled...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals’ SequestOx™ Study Results Expected in July
May 25, 2017 07:00 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 25, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), today announced that top-line results for its reformulated SequestOx™ study are...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 3rd Quarter 2017 Financial Results on February 13, 2017
February 07, 2017 08:00 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Pharmaceuticals, Inc. Logo
Elite Announces U.S. FDA Priority Review Designation for SequestOx™ NDA
March 17, 2016 07:00 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced that the New Drug Application (NDA) for SequestOXTM...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals, Inc. Reports Strong Growth for Second Quarter of Fiscal Year 2016
November 09, 2015 16:37 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced results for the quarter ended September 30, 2015, the second...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss 1st Quarter 2016 Financial Results on August 11, 2015
August 06, 2015 08:00 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
June 16, 2015 10:33 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 16, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the issuance of U.S. Patent No. 9,056,054 entitled...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
April 22, 2014 07:41 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., April 22, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the issuance of U.S. Patent No. 8,703,186 titled...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
March 10, 2014 07:46 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 10, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the expansion of intellectual property protection surrounding...